4-Antibody AG gained further validation for its Retrocyte Display proprietary human antibody platform, in the shape of a collaboration agreement with Human Genome Sciences Inc. (HGS), which will initially entail two discovery programs involving HGS-supplied targets. (BioWorld International)

LONDON – Drug delivery specialist Lipoxen plc is selling a majority, £12.8 million (US$20.9 million), stake in the company to SynBio LLC, a firm that is majority-owned by the government of Russia, as one of a series of moves to transform itself into a mainstream drug developer. (BioWorld International)